| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-95 |
Sentence |
denotes |
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. |
| T1 |
0-95 |
Sentence |
denotes |
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. |
| T2 |
96-107 |
Sentence |
denotes |
BACKGROUND: |
| T2 |
96-107 |
Sentence |
denotes |
BACKGROUND: |
| T3 |
108-307 |
Sentence |
denotes |
Interstitial fibrosis is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends on activation and differentiation of fibroblasts into myofibroblasts (MyoFb). |
| T3 |
108-307 |
Sentence |
denotes |
Interstitial fibrosis is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends on activation and differentiation of fibroblasts into myofibroblasts (MyoFb). |
| T4 |
308-392 |
Sentence |
denotes |
Recent clinical evidence suggests that in late-stage HF, fibrosis is not reversible. |
| T4 |
308-392 |
Sentence |
denotes |
Recent clinical evidence suggests that in late-stage HF, fibrosis is not reversible. |
| T5 |
393-404 |
Sentence |
denotes |
OBJECTIVES: |
| T5 |
393-404 |
Sentence |
denotes |
OBJECTIVES: |
| T6 |
405-547 |
Sentence |
denotes |
The study aims to examine the degree of differentiation of cardiac MyoFb in end-stage HF and the potential for their phenotypic reversibility. |
| T6 |
405-547 |
Sentence |
denotes |
The study aims to examine the degree of differentiation of cardiac MyoFb in end-stage HF and the potential for their phenotypic reversibility. |
| T7 |
548-556 |
Sentence |
denotes |
METHODS: |
| T7 |
548-556 |
Sentence |
denotes |
METHODS: |
| T8 |
557-725 |
Sentence |
denotes |
Fibroblasts were isolated from the left ventricle of the explanted hearts of transplant recipients (ischemic and dilated cardiomyopathy), and from nonused donor hearts. |
| T8 |
557-725 |
Sentence |
denotes |
Fibroblasts were isolated from the left ventricle of the explanted hearts of transplant recipients (ischemic and dilated cardiomyopathy), and from nonused donor hearts. |
| T9 |
726-819 |
Sentence |
denotes |
Fibroblasts were maintained in culture without passaging for 4 or 8 days (treatment studies). |
| T9 |
726-819 |
Sentence |
denotes |
Fibroblasts were maintained in culture without passaging for 4 or 8 days (treatment studies). |
| T10 |
820-931 |
Sentence |
denotes |
Phenotyping included functional testing, immunostaining, and expression studies for markers of differentiation. |
| T10 |
820-931 |
Sentence |
denotes |
Phenotyping included functional testing, immunostaining, and expression studies for markers of differentiation. |
| T11 |
932-1023 |
Sentence |
denotes |
These data were complemented with immunohistology and expression studies in tissue samples. |
| T11 |
932-1023 |
Sentence |
denotes |
These data were complemented with immunohistology and expression studies in tissue samples. |
| T12 |
1024-1032 |
Sentence |
denotes |
RESULTS: |
| T12 |
1024-1032 |
Sentence |
denotes |
RESULTS: |
| T13 |
1033-1143 |
Sentence |
denotes |
Interstitial fibrosis with cross-linked collagen is prominent in HF hearts, with presence of activated MyoFbs. |
| T13 |
1033-1143 |
Sentence |
denotes |
Interstitial fibrosis with cross-linked collagen is prominent in HF hearts, with presence of activated MyoFbs. |
| T14 |
1144-1253 |
Sentence |
denotes |
Tissue levels of transforming growth factor (TGF)-β1, lysyl oxidase, periostin, and osteopontin are elevated. |
| T14 |
1144-1253 |
Sentence |
denotes |
Tissue levels of transforming growth factor (TGF)-β1, lysyl oxidase, periostin, and osteopontin are elevated. |
| T15 |
1254-1405 |
Sentence |
denotes |
Fibroblastic cells isolated from HF hearts are predominantly MyoFb, proliferative or nonproliferative, with mature α-smooth muscle actin stress fibers. |
| T15 |
1254-1405 |
Sentence |
denotes |
Fibroblastic cells isolated from HF hearts are predominantly MyoFb, proliferative or nonproliferative, with mature α-smooth muscle actin stress fibers. |
| T16 |
1406-1496 |
Sentence |
denotes |
HF MyoFb express high levels of profibrotic cytokines and the TGF-β1 pathway is activated. |
| T16 |
1406-1496 |
Sentence |
denotes |
HF MyoFb express high levels of profibrotic cytokines and the TGF-β1 pathway is activated. |
| T17 |
1497-1742 |
Sentence |
denotes |
Inhibition of TGF-β1 receptor kinase in HF MyoFb promotes dedifferentiation of MyoFb with loss of α-smooth muscle actin and depolymerization of stress fibers, and reduces the expression of profibrotic genes and cytokines levels to non-HF levels. |
| T17 |
1497-1742 |
Sentence |
denotes |
Inhibition of TGF-β1 receptor kinase in HF MyoFb promotes dedifferentiation of MyoFb with loss of α-smooth muscle actin and depolymerization of stress fibers, and reduces the expression of profibrotic genes and cytokines levels to non-HF levels. |
| T18 |
1743-1754 |
Sentence |
denotes |
CONCLUSION: |
| T18 |
1743-1754 |
Sentence |
denotes |
CONCLUSION: |
| T19 |
1755-1957 |
Sentence |
denotes |
MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb. |
| T19 |
1755-1957 |
Sentence |
denotes |
MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb. |